Acute-on-Chronic Liver Failure: Competitive Landscape

This reports provides a data-driven overview of the current and future competitive landscape in Acute-on-Chronic Liver Failure therapeutics.

GlobalData epidemiologists estimated that there are 71,713 diagnosed incident cases of acute-on-chronic liver failure (ACLF) in 2024, which is expected to increase to 73,804 diagnosed incident cases by 2028.

Currently there are no approved therapies for ACLF.

There are currently no candidates in the late-stage development pipeline (Phase III and pre-registration) for ACLF.

Over the past decade, 71 trials have been initiated for ACLF. The years 2019 and 2023 saw the most trials initiated, with 11 trials each.

Over the decades, ACLF-related deals have primarily taken place in North America, Europe, and Asia-Pacific. In North America, 66.7% of deals were mergers while 33.3% were acquisitions.

Scope

GlobalData's Acute-on-Chronic Liver Failure: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Acute-on-Chronic Liver Failure market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Acute-on-Chronic Liver Failure market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.